Dorottya Gergő

Ms. Dorottya Gergő

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in Journal of Functional Foods
Verified
Journal Article
Open access
ATAndrea Tóth-Mészáros
Andrea Tóth-Mészáros
GGGantsetseg Garmaa
Gantsetseg Garmaa
PHPéter Hegyi
Péter Hegyi
BABanvolgyi Andras
Banvolgyi Andras
BFBánk Fenyves
Bánk Fenyves
Dezső CsuporDezső Csupor
Dezső Csupor

Verified
Journal Article
Open access
PDF file
Dorottya GergőDorottya Gergő
Dorottya Gergő
GGGantsetseg Garmaa
Gantsetseg Garmaa
ATAndrea Tóth-Mészáros
Andrea Tóth-Mészáros
DNDo To Uyen Nguyen
Do To Uyen Nguyen
PFPéter Fehérvári
Péter Fehérvári
Dezső CsuporDezső Csupor
Dezső Csupor
Background: Nausea and vomiting frequently occur during postoperative recovery, chemotherapy, and pregnancy. While peppermint oil is traditionally used to relieve these symptoms, its efficacy remains uncertain. This systematic review and meta-analysis evaluates the efficacy of peppermint oil inhalation for postoperative (PONV), chemotherapy-induced (CINV), and pregnancy-related nausea and vomiting (NVP). Methods: Following PRISMA guidelines, we searched five databases (Scopus, Embase, the Cochrane Central Register of Controlled Trials, MEDLINE, and Web of Science) in November 2022, with an update in December 2024. Randomised controlled trials were included, comparing peppermint oil inhalation to a control in patients with PONV, CINV, and NVP. Separate meta-analyses were conducted for each patient group using R, focusing on the severity of the nausea and vomiting. Results: Nineteen RCTs were included. In three PONV studies, peppermint oil inhalation was associated with a reduction in nausea 2 to 6 h after the intervention (MD: −0.60 points, 95% confidence interval (CI): −0.77 to −0.44, p = 0.004). In three NVP studies, daily peppermint oil treatment was linked to lower symptom severity at 48 h (MD: −0.51, 95% CI: −0.78 to −0.24, p = 0.015) and 96 h (MD: −0.68, 95% CI: −1.09 to −0.27, p = 0.019). In three CINV studies, peppermint oil inhalation appeared to reduce symptoms at all time points, with the most notable reduction at 48 h (MD: −2.23, 95% CI: −3.13 to −1.34, p < 0.001) and 72 h (MD: −2.41, 95% CI: −3.96 to −0.86, p = 0.010). Conclusions: Peppermint oil inhalation may be a promising complementary therapy for reducing nausea and vomiting in postoperative, chemotherapy, and pregnancy settings.

26 August 2025 in Physica Medica
Verified
Journal Article
Open access
BBBrúnó B Balázs
Brúnó B Balázs
DLDavid Laczkó
David Laczkó
Dorottya GergőDorottya Gergő
Dorottya Gergő
BSBence Szabó
Bence Szabó
GDGabor Z. Duray
Gabor Z. Duray
IÉIstván F. Édes
István F. Édes
Radiation exposure is a well-recognized occupational hazard for catheterization lab personnel. However, the extent of exposure disparities among different staff roles remains unclear. Existing research primarily focuses on primary operators, leaving a gap in understanding radiation risks for ancillary staff. This study aims to evaluate how staff positioning and shielding affect radiation exposure, focusing on disparities between primary operators and ancillary staff during fluoroscopy-guided cardiovascular procedures. After a systematic search across five databases on November 20, 2023, we included studies reporting radiation data for coronary angiographies, structural heart interventions, electrophysiological procedures, or endovascular aorta interventions, with at least one ancillary staff member in prespecified positions. Radiation exposures were compared relative to the primary operator using the Ratio of Means (ROM) during meta-analysis. Risk of Bias was assessed using RoB-2 or ROBINS-E. The review protocol was registered as CRD42023484491. Our meta-analysis, based on 8116 measurements from 3091 procedures across 23 studies, suggests that personnel at the patient's head without shielding may experience higher radiation exposure than primary operators (ROM 1.77, 95% CI: 0.75-4.18), although this difference didn't reach statistical significance. Shielded workers at the head or in secondary/assistant positions received significantly lower radiation than primary operators (ROM 0.26, 95% CI: 0.12-0.57; ROM 0.33, 95% CI: 0.25-0.43). Our results suggest a potential disparity in radiation exposure among catheterization laboratory personnel, with unshielded workers at the patient's head tending to receive the highest levels of exposure. Dedicated shielding solutions and attention to all personnel are imperative.

19 May 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
RMRegina Molnár
Regina Molnár
BBBlanka Rebeka Bódy
Blanka Rebeka Bódy
BVBoróka Varga
Boróka Varga
RTRéka Tóth
Réka Tóth
TKTamás Kói
Tamás Kói
APAndrea Párniczky
Andrea Párniczky

Verified
Journal Article
Open access
PDF file
Dorottya GergőDorottya Gergő
Dorottya Gergő
ATAndrea Tóth-Mészáros
Andrea Tóth-Mészáros
AWAlexander Schulze Wenning
Alexander Schulze Wenning
PFPéter Fehérvári
Péter Fehérvári
DNDo To Uyen Nguyen
Do To Uyen Nguyen
Dezső CsuporDezső Csupor
Dezső Csupor
Background: Gastrointestinal endoscopy is crucial for diagnosing colorectal cancer and inflammatory bowel diseases, but its effectiveness can be impacted by peristalsis, poor bowel preparation, and inadequate withdrawal time. Conventional antispasmodics, though effective, may not be suitable for elderly patients or those with comorbidities. L-menthol, derived from peppermint oil, has emerged as a safer alternative. Through calcium channel blockade, L-menthol promotes GI smooth muscle relaxation. This study evaluated L-menthol’s efficacy and safety as a potential alternative to antispasmodic agents in endoscopy. Methods: Following PRISMA2020 guidelines and the Cochrane Handbook, we conducted a systematic review and meta-analysis of randomized controlled trials involving adults undergoing endoscopy, comparing L-menthol to placebo. The primary outcome was the adenoma detection rate, with secondary outcomes, including severity of peristalsis, safety, withdrawal time, and ease of examination. We searched five databases on 31 May 2023, with updates on 20 October 2024. Results: Fourteen studies were included. L-menthol reduced peristalsis during colonoscopy and upper endoscopy, achieving a suppression rate of 55.9% (560/1002 patients; odds ratio (OR) = 3.88, 95% confidence interval (95% CI): 2.13–7.07), which improved mucosal visualization. It improved ease of examination (OR = 2.53, 95% CI: 1.35–4.73), allowing endoscopists to perform procedures with less technical difficulty. However, L-menthol had no significant impact on the adenoma detection rate (OR = 1.06, 95% CI: 0.69–1.64), indicating no added benefit for lesion detection, and did not prolong withdrawal time (MD = 3.24 s, 95% CI: −101.05–107.53). Adverse event rates remained low and comparable to placebo (OR = 0.97, 95% CI: 0.74–1.27). Conclusions: L-menthol reduces peristalsis and enhances ease of examination without adverse events. Although its effect on the adenoma detection rate remains inconclusive, its antispasmodic properties make it a promising alternative for patients who cannot tolerate conventional agents.

25 June 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
DKDénes Kleiner
Dénes Kleiner
IHIstván Horváth
István Horváth
DMDora Matis
Dora Matis
RNRita Nagy
Rita Nagy
Dorottya GergőDorottya Gergő
Dorottya Gergő
Dezső CsuporDezső Csupor
Dezső Csupor
Background/Objectives: Nabiximols, a standardized extract of Cannabis sativa, has been approved as an add-on therapy for patients with moderate to severe spasticity associated with multiple sclerosis (MS). Moreover, current Italian treatment algorithms suggest that cannabis-based therapies may have further relevance in the management of MS. The aim of our systematic review and meta-analysis was to assess the effectiveness of nabiximols in relieving symptoms other than spasticity in adult MS patients. Methods: A systematic search was conducted in Web of Science, MEDLINE (via PubMed), Cochrane CENTRAL and Embase on September 10, 2025. Study selection was performed according to the predefined PROSPERO protocol (CRD42022329952). Data were combined into a common denominator and examined using a random-effects model with meta-regression expressed as mean difference (MD) and a 95% confidence interval (CI). Risk of bias was assessed using the Cochrane risk of bias instrument (RoB2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. Results: Of the 49 eligible articles, 25 were included in the statistical analysis (2949 patients). Significant improvements in spasm quality (MD = −16.87; 95% CI = (−29.75)–(−3.99)), bladder function (MD = −16.38; 95% CI = (−22.18)–(−10.58)), sleep disruption (MD = −15.75; 95% CI = (−22.02)–(−9.49)) and gait function (timed walk MD(s) = −5.31; 95% CI(s) = (−9.88)–(−0.74)) were observed. Time-dependency was not significant. The subject global impression of change (SGIC) improved significantly after the first month (odds ratio (OR) = 1.69; 95% CI = (1.30)–(2.18)). Conclusion: Beyond spasticity, nabiximols may represent a signal of benefit for bladder function, sleep disruption, spasm quality, and gait function in MS, in line with the “spasticity-plus” concept. However, the evidence certainty was low to very low, and these findings should be considered exploratory.